JP2024518536A5 - - Google Patents
Info
- Publication number
- JP2024518536A5 JP2024518536A5 JP2023570108A JP2023570108A JP2024518536A5 JP 2024518536 A5 JP2024518536 A5 JP 2024518536A5 JP 2023570108 A JP2023570108 A JP 2023570108A JP 2023570108 A JP2023570108 A JP 2023570108A JP 2024518536 A5 JP2024518536 A5 JP 2024518536A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- optionally
- formulation
- proline
- nacl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187476P | 2021-05-12 | 2021-05-12 | |
| US63/187,476 | 2021-05-12 | ||
| PCT/US2022/029043 WO2022241148A1 (en) | 2021-05-12 | 2022-05-12 | Antibody composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518536A JP2024518536A (ja) | 2024-05-01 |
| JP2024518536A5 true JP2024518536A5 (https=) | 2025-05-16 |
Family
ID=82156644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570108A Pending JP2024518536A (ja) | 2021-05-12 | 2022-05-12 | 抗体組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240216506A1 (https=) |
| EP (1) | EP4337257A1 (https=) |
| JP (1) | JP2024518536A (https=) |
| KR (1) | KR20240021800A (https=) |
| CN (1) | CN117615788A (https=) |
| AU (1) | AU2022274319A1 (https=) |
| CA (1) | CA3218343A1 (https=) |
| WO (1) | WO2022241148A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| AR070316A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| PH12012501364A1 (en) * | 2010-01-15 | 2012-10-22 | Amgen K A Inc | Antibody formulation and therapeutic regimens |
| JP6345123B2 (ja) * | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| KR102385802B1 (ko) * | 2014-05-07 | 2022-04-13 | 다케다 야쿠힝 고교 가부시키가이샤 | Gm-csf 중화 화합물을 포함하는 액체 제제 |
| CN115925932A (zh) * | 2015-04-15 | 2023-04-07 | 安奈普泰斯生物有限公司 | 针对白细胞介素36受体（il-36r）的抗体 |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| SI4190355T1 (sl) * | 2017-04-28 | 2025-02-28 | Amgen Inc. | Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe |
| CN110151988A (zh) * | 2018-02-11 | 2019-08-23 | 百奥泰生物制药股份有限公司 | 一种靶向治疗TNF-α相关疾病的人抗体制剂 |
| BR112020016738A2 (pt) * | 2018-03-14 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada |
| TW202037604A (zh) * | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| WO2020146527A1 (en) * | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| IL286100B2 (en) * | 2019-03-08 | 2024-12-01 | Boehringer Ingelheim Int | Anti-il-36r antibody formulations |
| KR20230035355A (ko) * | 2020-07-03 | 2023-03-13 | 씨에스엘 이노베이션 피티와이 엘티디 | 인자 xii 항원 결합 단백질의 고농도 제형 |
| WO2022132636A1 (en) * | 2020-12-14 | 2022-06-23 | AmMax Bio, Inc. | High concentration formulations of anti-csf1 and anti-csf1r antibodies |
| JP2023554087A (ja) * | 2020-12-16 | 2023-12-26 | シーエスエル イノベーション プロプライアタリー リミティド | タンパク質製剤及びその使用 |
-
2022
- 2022-05-12 JP JP2023570108A patent/JP2024518536A/ja active Pending
- 2022-05-12 AU AU2022274319A patent/AU2022274319A1/en active Pending
- 2022-05-12 EP EP22732712.9A patent/EP4337257A1/en active Pending
- 2022-05-12 CA CA3218343A patent/CA3218343A1/en active Pending
- 2022-05-12 KR KR1020237042908A patent/KR20240021800A/ko active Pending
- 2022-05-12 WO PCT/US2022/029043 patent/WO2022241148A1/en not_active Ceased
- 2022-05-12 CN CN202280048644.0A patent/CN117615788A/zh active Pending
- 2022-05-12 US US18/560,317 patent/US20240216506A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515271A5 (https=) | ||
| JP2024518536A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| JP2020518600A5 (https=) | ||
| HRP20240182T1 (hr) | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020509031A5 (https=) | ||
| JP2019523295A5 (https=) | ||
| JP2011528902A5 (https=) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| JP2011506483A5 (https=) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| CA2707400A1 (en) | Method for treating bone fracture with anti-sclerostin antibodies | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| JP2012504955A5 (https=) | ||
| JP2015522252A5 (https=) | ||
| IL316404A (en) | A safe and effective method for treating psoriasis with a specific anti-IL23 antibody | |
| ES2909722T3 (es) | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada | |
| JP2019534003A5 (https=) | ||
| JP2024507948A5 (https=) | ||
| JP2020502261A5 (https=) | ||
| JP2021531732A5 (https=) | ||
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| JP2017520572A5 (https=) |